SG11201809456UA - Interferon beta antibodies and uses thereof - Google Patents
Interferon beta antibodies and uses thereofInfo
- Publication number
- SG11201809456UA SG11201809456UA SG11201809456UA SG11201809456UA SG11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- avenue
- street
- antibodies
- boston
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title abstract 3
- 108090000467 Interferon-beta Proteins 0.000 title abstract 3
- 229960001388 interferon-beta Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 241000036313 Cupressus torulosa Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 November 2017 (02.11.2017) ill Hu omits Holm o 101101MIR HMV 011 (10) International Publication Number WO 2017/189983 Al WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/24 (2006.01) (21) International Application Number: PCT/US2017/030089 (22) International Filing Date: 28 April 2017 (28.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/329,327 29 April 2016 (29.04.2016) US 62/339,709 20 May 2016 (20.05.2016) US 62/483,669 10 April 2017 (10.04.2017) US (71) Applicants: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). THE BRIGHAM AND WOMEN'S HOSPITAL, INC. [US/US]; 75 Francis Street, Boston, MA 02115 (US). (72) Inventors: GULLA, Stefano, V.; 345 D. Street, Unit 13, Boston, MA 02127 (US). HUARD, Christine; 58 Cherry Street, #14, Somerville, MA 02144 (US). BUHLMANN, Janet, Elizabeth; 30 Gardner Rd., Apt. 4b, Brookline, MA 02445 (US). ALMAGRO, Juan, Carlos; 320 Con- cord Avenue, Cambridge, MA 02138 (US). KODANGAT- TIL, Sreekumar, R.; 517 Concord Avenue, Lexington, MA 02421 (US). GREENBERG, Steven, A.; 46 New- tonville Avenue, Newton, MA 02458 (US). LAVALLIE, Edward, Roland; 113 Ann Lee Road, Harvard, MA 01451 (US). BENNETT, Eric, M.; 45 Morningside Drive, Ar- lington, MA 02474 (US). MOSYAK, Lidia; 92 Littefield Road, Newton, MA 02469 (US). HALL, James, Perry; 19 Lanes End Road, Stow, MA 01775 (US). COYLE, Antho- ny, John; 12 Union Park, Boston, MA 02118 (US). (74) Agent: MANGASARIAN, Karen et al.; Ropes & Gray Llp, 1211 Avenue Of The Americas, New York, NY 10036 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 00 00 1-1 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) with sequence listing part of description (Rule 5.2(a)) N (54) Title: INTERFERON BETA ANTIBODIES AND USES THEREOF 1-1 0 (57) : The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta \" (IFNp). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes. C
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329327P | 2016-04-29 | 2016-04-29 | |
| US201662339709P | 2016-05-20 | 2016-05-20 | |
| US201762483669P | 2017-04-10 | 2017-04-10 | |
| PCT/US2017/030089 WO2017189983A1 (en) | 2016-04-29 | 2017-04-28 | Interferon beta antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809456UA true SG11201809456UA (en) | 2018-11-29 |
Family
ID=59215947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809456UA SG11201809456UA (en) | 2016-04-29 | 2017-04-28 | Interferon beta antibodies and uses thereof |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10829553B2 (en) |
| EP (2) | EP4273165A3 (en) |
| JP (2) | JP6799076B2 (en) |
| KR (1) | KR102527840B1 (en) |
| CN (1) | CN109069606B (en) |
| AU (1) | AU2017258492B2 (en) |
| BR (1) | BR112018072118A2 (en) |
| CA (1) | CA2965652A1 (en) |
| CO (1) | CO2018012497A2 (en) |
| DK (1) | DK3448419T5 (en) |
| ES (1) | ES2950288T3 (en) |
| FI (1) | FI3448419T3 (en) |
| HR (1) | HRP20230605T1 (en) |
| HU (1) | HUE063621T2 (en) |
| IL (1) | IL262244B2 (en) |
| MX (1) | MX2018013222A (en) |
| MY (1) | MY194084A (en) |
| NZ (1) | NZ747225A (en) |
| PE (1) | PE20190371A1 (en) |
| PH (1) | PH12018502275A1 (en) |
| PL (1) | PL3448419T3 (en) |
| PT (1) | PT3448419T (en) |
| RU (1) | RU2750454C2 (en) |
| SA (1) | SA518400327B1 (en) |
| SG (1) | SG11201809456UA (en) |
| SI (1) | SI3448419T1 (en) |
| TW (1) | TWI776808B (en) |
| WO (1) | WO2017189983A1 (en) |
| ZA (1) | ZA201806682B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201809456UA (en) | 2016-04-29 | 2018-11-29 | Pfizer | Interferon beta antibodies and uses thereof |
| EP4410378A3 (en) | 2016-07-01 | 2024-10-09 | Resolve Therapeutics, LLC | Optimized binuclease fusions and methods |
| JP7374091B2 (en) | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | Soluble interferon receptors and their uses |
| EP3784699A4 (en) | 2018-04-25 | 2022-04-13 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
| CN115925950A (en) * | 2019-01-31 | 2023-04-07 | 广东旋玉健康生物科技有限公司 | Novel anti-IFNAR 1 antibodies |
| KR20220103721A (en) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Humanized Antibodies to TNF-Like Ligand 1A (TL1A) and Uses Thereof |
| CN114733455B (en) * | 2022-04-15 | 2023-02-14 | 北京田园奥瑞生物科技有限公司 | Method for rapidly parting mammal sperms by utilizing biologically modified beta-cyclodextrin nano magnetic particles |
| TW202426493A (en) * | 2022-09-22 | 2024-07-01 | 美商輝瑞大藥廠 | METHODS OF TREATMENT WITH IFNß ANTIBODIES |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6682896B1 (en) * | 1988-10-14 | 2004-01-27 | Schering Aktiengesellschaft | Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof |
| WO1990003982A1 (en) * | 1988-10-14 | 1990-04-19 | Triton Biosciences, Inc. | Peptides representing epitopic sites on r-ifn-beta, antibodies thereto, and uses thereof |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL108584A (en) * | 1994-02-07 | 2008-03-20 | Yeda Res & Dev | Cloning of interferon -alpha/beta binding protein |
| ZA9811070B (en) | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| KR100708398B1 (en) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | Humanized antibody and process for preparing same |
| EP1575517B1 (en) | 2002-12-24 | 2012-04-11 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
| CN103596983B (en) * | 2011-04-07 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | Anti-FGFR4 antibody and using method |
| CN102898521A (en) * | 2011-07-26 | 2013-01-30 | 上海市免疫学研究所 | Anti-beta-interferon monoclonal antibody and its application |
| US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| KR20180020296A (en) * | 2015-06-26 | 2018-02-27 | 바이오버라티브 유에스에이 인코포레이티드 | How to treat autoimmune and allogeneic immune disorders |
| SG11201809456UA (en) | 2016-04-29 | 2018-11-29 | Pfizer | Interferon beta antibodies and uses thereof |
-
2017
- 2017-04-28 SG SG11201809456UA patent/SG11201809456UA/en unknown
- 2017-04-28 PL PL17733171.7T patent/PL3448419T3/en unknown
- 2017-04-28 PT PT177331717T patent/PT3448419T/en unknown
- 2017-04-28 US US15/581,079 patent/US10829553B2/en active Active
- 2017-04-28 HU HUE17733171A patent/HUE063621T2/en unknown
- 2017-04-28 AU AU2017258492A patent/AU2017258492B2/en active Active
- 2017-04-28 HR HRP20230605TT patent/HRP20230605T1/en unknown
- 2017-04-28 KR KR1020187034153A patent/KR102527840B1/en active IP Right Grant
- 2017-04-28 TW TW106114362A patent/TWI776808B/en active
- 2017-04-28 FI FIEP17733171.7T patent/FI3448419T3/en active
- 2017-04-28 CN CN201780025961.XA patent/CN109069606B/en active Active
- 2017-04-28 CA CA2965652A patent/CA2965652A1/en active Pending
- 2017-04-28 ES ES17733171T patent/ES2950288T3/en active Active
- 2017-04-28 RU RU2018141839A patent/RU2750454C2/en active
- 2017-04-28 BR BR112018072118-2A patent/BR112018072118A2/en unknown
- 2017-04-28 IL IL262244A patent/IL262244B2/en unknown
- 2017-04-28 WO PCT/US2017/030089 patent/WO2017189983A1/en active Application Filing
- 2017-04-28 MY MYPI2018703975A patent/MY194084A/en unknown
- 2017-04-28 NZ NZ747225A patent/NZ747225A/en unknown
- 2017-04-28 JP JP2018556490A patent/JP6799076B2/en active Active
- 2017-04-28 SI SI201731384T patent/SI3448419T1/en unknown
- 2017-04-28 EP EP23177086.8A patent/EP4273165A3/en active Pending
- 2017-04-28 DK DK17733171.7T patent/DK3448419T5/en active
- 2017-04-28 PE PE2018002056A patent/PE20190371A1/en unknown
- 2017-04-28 MX MX2018013222A patent/MX2018013222A/en unknown
- 2017-04-28 EP EP17733171.7A patent/EP3448419B1/en active Active
-
2018
- 2018-10-08 ZA ZA2018/06682A patent/ZA201806682B/en unknown
- 2018-10-25 PH PH12018502275A patent/PH12018502275A1/en unknown
- 2018-10-28 SA SA518400327A patent/SA518400327B1/en unknown
- 2018-11-21 CO CONC2018/0012497A patent/CO2018012497A2/en unknown
-
2020
- 2020-11-09 US US17/092,998 patent/US11858986B2/en active Active
- 2020-11-19 JP JP2020192541A patent/JP7102489B2/en active Active
-
2023
- 2023-11-16 US US18/511,744 patent/US20240174742A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809456UA (en) | Interferon beta antibodies and uses thereof | |
| SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201803679TA (en) | Antibodies and antibody fragments for site-specific conjugation | |
| SG11201811193TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201900154VA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201803676PA (en) | Site specific her2 antibody drug conjugates | |
| SG11201408228QA (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201909466RA (en) | Human anti-semaphorin 4d antibody |